Martin S. Angst

Publications

• Opioid Pharmacotherapy for Chronic Non-cancer Pain. Chapman CR, Lipschitz DL, Angst MS, Chou R, Denisco RC, Donaldson GW, Fine PG, Foley KM, Gallagher RM, Gilson AM, Inturrisi CE, Haddox JD, Susan SD, Jick SS, Lipman AG, Loser JD, Noble M, Porter L, Rowbotham MC, Schoelles KM, Turk DC, Volinn E, Von Korff MR, Webster LR, Weisner CM. J Pain. In Press
• No evidence for the development of acute tolerance to analgesic, respiratory depressant and sedative opioid effects in humans. Angst MS, Chu LF, Tingle MS, Shafer SL, Clark JD, Drover DR. Pain. 2009; 142 (1-2): 17-26
• Determining heat and mechanical pain threshold in inflamed skin of human subjects. Angst MS, Tingle M, Phillips NG, Carvalho B. J Vis Exp. 2009; (23)
• Selective Antagonism of Opioid-Induced Ventilatory Depression by an Ampakine Molecule in Humans Without Loss of Opioid Analgesia. Oertel BG, Felden L, Tran PV, Bradshaw MH, Angst MS, Schmidt H, Johnson S, Greer JJ, Geisslinger G, Varney MA, Lötsch J. Clin Pharmacol Ther. 2009
• Epidural interferon gamma-immunoreactivity: A biomarker for lumbar nerve root irritation. Scuderi GJ, Cuellar JM, Gabrovsky V, Yeomans DC, Carragee EJ, Angst MS. Spine. 2009: 34 2311-2317
• Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations. Chu LF, Angst MS, Clark D. Clin J Pain. 2008 Jul-Aug; 24 (6): 479-96
• Human in-vivo bioassay for the tissue-specific measurement of nociceptive and inflammatory mediators. Angst MS, Tingle M, Schmelz M, Carvalho B, Yeomans DC. J Vis Exp. 2008; (22)
• Local and systemic release of cytokines, nerve growth factor, prostaglandin E2, and substance P in incisional wounds and serum following cesarean delivery. Carvalho B, Clark DJ, Angst MS. J Pain. 2008; 9 (7): 650-7
• Chronic morphine administration enhances nociceptive sensitivity and local cytokine production after incision. Liang D, Shi X, Qiao Y, Angst MS, Yeomans DC, Clark JD. Mol Pain. 2008: 4 7
• Collecting and measuring nociceptive and inflammatory mediators in surgical wounds. Carvalho B, Clark DJ, Yeomans D, Angst MS. J Vis Exp. 2008; (20)
• Cytokine profile in human skin in response to experimental inflammation, noxious stimulation, and administration of a COX-inhibitor: a microdialysis study. Angst MS, Clark JD, Carvalho B, Tingle M, Schmelz M, Yeomans DC. Pain. 2008; 139 (1): 15-27
• Morphine reduces local cytokine expression and neutrophil infiltration after incision. Clark JD, Shi X, Li X, Qiao Y, Liang D, Angst MS, Yeomans DC. Mol Pain. 2007: 3 28
• Comment on Koltzenburg et al.: Differential sensitivity of three experimental pain models in detecting the analgesic effects of transdermal fentanyl and buprenorphine. Pain 2006;126:165-74. Angst MS, Clark JD. Pain. 2007; 128 (3): 292-4
• When opioids cause pain. Davis MP, Shaiova LA, Angst MS. J Clin Oncol. 2007; 25 (28): 4497-8
• Opioid-induced hyperalgesia: a qualitative systematic review. Angst MS, Clark JD. Anesthesiology. 2006; 104 (3): 570-87
• Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: a preliminary prospective study. Chu LF, Clark DJ, Angst MS. J Pain. 2006; 7 (1): 43-8
• Experimental heat pain for detecting pregnancy-induced analgesia in humans. Carvalho B, Angst MS, Fuller AJ, Lin E, Mathusamy AD, Riley ET. Anesth Analg. 2006; 103 (5): 1283-7
• Blockade of the complement C5a receptor reduces incisional allodynia, edema, and cytokine expression. Clark JD, Qiao Y, Li X, Shi X, Angst MS, Yeomans DC. Anesthesiology. 2006; 104 (6): 1274-82
• Pharmacology of drugs formulated with DepoFoam: a sustained release drug delivery system for parenteral administration using multivesicular liposome technology. Angst MS, Drover DR. Clin Pharmacokinet. 2006; 45 (12): 1153-76
• Activation of naloxone-sensitive and -insensitive inhibitory systems in a human pain model. Koppert W, Filitz J, Tröster A, Ihmsen H, Angst M, Flor H, Schüttler J, Schmelz M. J Pain. 2005; 6 (11): 757-64
• Management of perioperative pain in patients chronically consuming opioids. Carroll IR, Angst MS, Clark JD. Reg Anesth Pain Med. 2004 Nov-Dec; 29 (6): 576-91
• Dexmedetomidine and opioid interactions: defining the role of dexmedetomidine for intensive care unit sedation. Maze M, Angst MS. Anesthesiology. 2004; 101 (5): 1059-61
• Comparative analgesic and mental effects of increasing plasma concentrations of dexmedetomidine and alfentanil in humans. Angst MS, Ramaswamy B, Davies MF, Maze M. Anesthesiology. 2004; 101 (3): 744-52
• The mu-opioid agonist remifentanil attenuates hyperalgesia evoked by blunt and punctuated stimuli with different potency: a pharmacological evaluation of the freeze lesion in humans. Lötsch J, Angst MS. Pain. 2003; 102 (1-2): 151-61
• The site of action of epidural fentanyl infusions in the presence of local anesthetics: a minimum local analgesic concentration infusion study in nulliparous labor. Ginosar Y, Columb MO, Cohen SE, Mirikatani E, Tingle MS, Ratner EF, Angst MS, Riley ET. Anesth Analg. 2003; 97 (5): 1439-45
• Naloxone provokes similar pain facilitation as observed after short-term infusion of remifentanil in humans. Koppert W, Angst M, Alsheimer M, Sittl R, Albrecht S, Schüttler J, Schmelz M. Pain. 2003; 106 (1-2): 91-9
• Seizure duration with remifentanil/methohexital vs. methohexital alone in middle-aged patients undergoing electroconvulsive therapy. Smith DL, Angst MS, Brock-Utne JG, DeBattista C. Acta Anaesthesiol Scand. 2003; 47 (9): 1064-6
• The site of action of epidural fentanyl in humans: the difference between infusion and bolus administration. Ginosar Y, Riley ET, Angst MS. Anesth Analg. 2003; 97 (5): 1428-38
• Short-term infusion of the mu-opioid agonist remifentanil in humans causes hyperalgesia during withdrawal. Angst MS, Koppert W, Pahl I, Clark DJ, Schmelz M. Pain. 2003; 106 (1-2): 49-57
• Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers. Drover DR, Angst MS, Valle M, Ramaswamy B, Naidu S, Stanski DR, Verotta D. Anesthesiology. 2002; 97 (4): 827-36
• Opioid-induced hyperalgesia and incisional pain. Li X, Angst MS, Clark JD. Anesth Analg. 2001; 93 (1): 204-9
• The relationship between tracheal width and left bronchial width: Implications for left-sided double-lumen tube selection. Brodsky JB, Malott K, Angst M, Fitzmaurice BG, Kee SP, Logan L. J Cardiothorac Vasc Anesth. 2001; 15 (2): 216-7
• A murine model of opioid-induced hyperalgesia. Li X, Angst MS, Clark JD. Brain Res Mol Brain Res. 2001; 86 (1-2): 56-62
• Pharmacodynamics of orally administered sustained- release hydromorphone in humans. Angst MS, Drover DR, Lötsch J, Ramaswamy B, Naidu S, Wada DR, Stanski DR. Anesthesiology. 2001; 94 (1): 63-73
• Painless Electrodiagnostic Current Perception Threshold and Pain Tolerance Threshold Values in CRPS Subjects and Healthy Controls: A Multi-Center Study Raj PP, Chado HN, Angst MS, et al.. Pain Practice. 2001: 1 53-60
• Orthotopic liver transplantation for carcinoid tumour metastatic to the liver: anesthetic management. Claure RE, Drover DD, Haddow GR, Esquivel CO, Angst MS. Can J Anaesth. 2000; 47 (4): 334-7
• Antinociceptive effects of morphine-6-glucuronide in homozygous MDR1a P-glycoprotein knockout and in wildtype mice in the hotplate test. Lötsch J, Tegeder I, Angst MS, Geisslinger G. Life Sci. 2000; 66 (24): 2393-403
• Insidious intoxication after morphine treatment in renal failure: delayed onset of morphine-6-glucuronide action. Angst MS, Bührer M, Lötsch J. Anesthesiology. 2000; 92 (5): 1473-6
• Lumbar epidural morphine in humans and supraspinal analgesia to experimental heat pain. Angst MS, Ramaswamy B, Riley ET, Stanski DR. Anesthesiology. 2000; 92 (2): 312-24
• Factors affecting the pharmacokinetic characteristics of rapacuronium. Fisher DM, Kahwaji R, Bevan D, Bikhazi G, Fragen RJ, Angst MS, Ornstein E, Matteo RS. Anesthesiology. 1999; 90 (4): 993-1000
• The relationship between the visual analog pain intensity and pain relief scale changes during analgesic drug studies in chronic pain patients. Angst MS, Brose WG, Dyck JB. Anesthesiology. 1999; 91 (1): 34-41
• Pharmacokinetics, cortisol release, and hemodynamics after intravenous and subcutaneous injection of human corticotropin-releasing factor in humans. Angst MS, Dyck JB, Azarnoff DL, Goldblum R, Ho B, Gfroerer T, Linton EA, Glynn BP, Shafer SL. Clin Pharmacol Ther. 1998; 64 (5): 499-510
• Dose-response function of epidural fentanyl versus sufentanil. Angst MS, Anesth Analg. 1998; 86 (4): 918-9
• A New Double-Lumen IV Infusion Set Reduces Pain on Injection of Propofol. Angst MS, Chris Tataru, Sean Mackey, Gary Zupfer, John B. Dyck, John G. Brock-Utne.. J Clin Anesth. 1997; (9)
• Dose-ranging study in younger adult and elderly patients of ORG 9487, a new, rapid-onset, short-duration muscle relaxant. Kahwaji R, Bevan DR, Bikhazi G, Shanks CA, Fragen RJ, Dyck JB, Angst MS, Matteo R. Anesth Analg. 1997; 84 (5): 1011-8
• Corticosteroid-induced stimulation of atrial natriuretic peptide in man. Saxenhofer H, Angst M, Weidmann P, Shaw SG, Ferrier C. Acta Endocrinol (Copenh). 1988; 118 (2): 179-86